Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

61 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

NCT01824420

Overactive Bladder

COMPLETED PHASE4

Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome

NCT01503580

Antimuscarinic Drug

COMPLETED NA

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

NCT01729819

Overactive Bladder

COMPLETED PHASE2

Prevalence and Risk Factors Nocturnal Polyuria in Female OAB

NCT03810027

Nocturia

COMPLETED

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

NCT01627145

Overactive Bladder Syndrome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women with urodynamic DO refractory to combined pharmacotherapy

We enrolled women with refractory detrusor overactivity, defined as ongoing symptoms after at least 1 month of treatment with either an anticholinergic or a β3-agonist. Eligible women received combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily for 12 weeks.

Combined pharmacotherapy

Intervention Type DRUG

Combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined pharmacotherapy

Combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anticholinergics or β3-agonist medication for at least 1 month.

Exclusion Criteria

* Neurological conditions or spinal cord injury, which could affect urologic function
* Advanced pelvic organ prolapse (pelvic organ prolapse quantification system stage II or above)
* Active urinary tract infection
* Contraindications to taking anticholinergic and β3-agonist medications

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No